Sort   by:  
 Page size 
UnknownBioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis.
Not available
S-EPMC3464084 | biostudies-literature
UnknownIDD16 negatively regulates stomatal initiation via trans-repression of SPCH in Arabidopsis.
Not available
S-EPMC6576023 | biostudies-literature
ProteomicsThe changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylati...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054332 | Pride
Human Lc-msms Hnscc Cetuximab resistance Acetylation 
ProteomicsThe changes in cetuximab resistant HNSCC cell lines (e.g., OECM1-cetuximabR and CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main phosphorylation sites in resistance cell lines.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the phosphorylation sites in wild-type and resistant cells. We proposed that the phosp...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054186 | Pride
Human Lc-msms Hnscc Cetuximab resistance Phosphorylation 
ProteomicsThe changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We collected serial passages of cetuximab resistance HNSCC cell lines to perform LC-MS/MS. We identified the IFN p...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054113 | Pride
Human Lc-msms Hnscc Cetuximab 
ProteomicsComparisons of Whole Saliva and Cell Free Saliva by DIA-Based Proteome Profiling
Saliva has emerged as a promising diagnostic resource due to its accessibility, non-invasiveness, and repeatability, enabling early disease detection and timely intervention. However, current studies often overlook the distinction between whole saliva (WS) and cell-free saliva (CFS). This study aims...
ORGANISM(S): Homo Sapiens 
2024-08-29 | PXD055371 |
UnknownTherapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy.
Not available
S-EPMC12711663 | biostudies-literature
ProteomicsProteogenomic landscape of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
We performed proteomic analysis of 115 ccRCC patients samples undergoing sunitinib treatment.
ORGANISM(S): Homo Sapiens 
2023-06-08 | PXD042844 |
ProteomicsProteogenomic Characterization of MiT Family Translocation Renal Cell Carcinoma
Comprehensive proteogenomic analysis of Microphthalmia Transcription Factor (MiT) family translocation renal cell carcinoma (tRCC) tumor and normal adjacent tissues was performed to elucidate the molecular landscape of these tumors.
ORGANISM(S): Homo Sapiens 
2022-07-20 | PXD035377 |
ProteomicsA Proteogenomic Analysis of Clear Cell Renal Cell Carcinoma in a Chinese Population
We performed proteomic analysis of 232 ccRCC patients samples.
ORGANISM(S): Homo Sapiens 
2022-04-16 | PXD030344 |
Sort   by:  
 Page size